Recent progress in orexin/hypocretin physiology and pharmacology

Biomolecular Concepts

Volumn 3, Issue 5, 2012, Pages 447-463

  Kukkonen, Jyrki P ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

G protein coupled receptor; hypocretin; neuropeptide; orexin; orexin receptor

Indexed keywords

EID: 84871864829     PISSN: 18685021     EISSN: 1868503X     Source Type: Journal    
DOI: 10.1515/bmc-2012-0013     Document Type: Review

References (150)

1. de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, Fukuhara C, Battenberg EL, Gautvik VT, Bartlett FS, Frankel WN, van den Pol AN, Bloom FE, Gautvik KM, Sutcliffe JG. The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 1998; 95: 322-7.
2. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JR, Buckingham RE, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu WS, Terrett JA, Elshourbagy NA, Bergsma DJ, Yanagisawa M. Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998; 92: 573-85.
3. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, Richardson JA, Williams SC, Xiong Y, Kisanuki Y, Fitch TE, Nakazato M, Hammer RE, Saper CB, Yanagisawa M. Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation. Cell 1999; 98: 437-51.
4. Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, Qiu X, de Jong PJ, Nishino S, Mignot E. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999; 98: 365-76.
5. Kukkonen JP, Holmqvist T, Ammoun S, A kerman KE. Functions of the orexinergic/hypocretinergic system. Am J Physiol Cell Physiol 2002; 283: C1567-91.
6. Congreve M, Marshall F. The impact of GPCR structures on pharmacology and structure-based drug design. Br J Pharmacol 2010; 159: 986-96.
7. Malherbe P, Roche O, Marcuz A, Kratzeisen C, Wettstein JG, Bissantz C. Mapping the binding pocket of dual antagonist almorexant to human orexin 1 and orexin 2 receptors: Comparison with the selective OX1 (SB-674042) and OX2 (EMPA) antagonists. Mol Pharmacol 2010; 78: 81-93.
8. Tran DT, Bonaventure P, Hack M, Mirzadegan T, Dvorak C, Letavic M, Carruthers N, Lovenberg T, Sutton SW. Chimeric, mutant orexin receptors show key interactions between orexin receptors, peptides and antagonists. Eur J Pharmacol 2011; 667: 120-8.
9. Putula J, Kukkonen JP. Mapping of the binding sites for the OX(1) orexin receptor antagonist, SB-334867, using orexin/ hypocretin receptor chimaeras. Neurosci Lett 2012; 506: 111-5.
10. Putula J, Turunen PM, Johansson L, Näsman J, Ra R, Korhonen L, Kukkonen JP. Orexin/hypocretin receptor chimaeras reveal structural features important for orexin peptide distinction. FEBS Lett 2011; 585: 1368-74.
11. Holmqvist T, Akerman KEO, Kukkonen JP. High specificity of human orexin receptors for orexins over neuropeptide Y and other neuropeptides. Neurosci Lett 2001; 305: 177-80.
12. Putula J, Turunen PM, Jäntti MH, Ekholm ME, Kukkonen JP. Agonist ligand discrimination by the two orexin receptors depends on the expression system. Neurosci Lett 2011; 494: 57-60.
13. Kukkonen JP. Regulation of receptor-coupling to (multiple) G-proteins. A challenge for basic research and drug discovery. Receptors Channels 2004; 10: 167-83.
14. Kenakin T. Functional selectivity and biased receptor signaling. J Pharmacol Exp Ther 2011; 336: 296-302.
15. Ammoun S, Holmqvist T, Shariatmadari R, Oonk HB, Detheux M, Parmentier M, A kerman KE, Kukkonen JP. Distinct recognition of OX1 and OX2 receptors by orexin peptides. J Pharmacol Exp Ther 2003; 305: 507-14.
16. Mazzocchi G, Malendowicz LK, Gottardo L, Aragona F, Nussdorfer GG. Orexin A stimulates cortisol secretion from human adrenocortical cells through activation of the adenylate cyclase-dependent signaling cascade. J Clin Endocrinol Metab 2001; 86: 778-82.
17. Roecker AJ, Coleman PJ. Orexin receptor antagonists: Medicinal chemistry and therapeutic potential. Curr Top Med Chem 2008; 8: 977-87.
18. Langmead CJ, Jerman JC, Brough SJ, Scott C, Porter RA, Herdon HJ. Characterisation of the binding of [ 3 H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. Br J Pharmacol 2004; 141: 340-6.
19. Hirose M, Egashira S, Goto Y, Hashihayata T, Ohtake N, Iwaasa H, Hata M, Fukami T, Kanatani A, Yamada K. N-Acyl 6, 7-dimethoxy-1, 2, 3, 4-Tetrahydroisoquinoline: The first orexin-2 receptor selective non-peptidic antagonist. Bioorg Med Chem Lett 2003; 13: 4497-9.
20. Willie JT, Chemelli RM, Sinton CM, Tokita S, Williams SC, Kisanuki YY, Marcus JN, Lee C, Elmquist JK, Kohlmeier KA, Leonard CS, Richardson JA, Hammer RE, Yanagisawa M. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: Molecular genetic dissection of non-REM and REM sleep regulatory processes. Neuron 2003; 38: 715-30.
21. Dugovic C, Shelton JE, Aluisio LE, Fraser IC, Jiang X, Sutton SW, Bonaventure P, Yun S, Li X, Lord B, Dvorak CA, Carruthers NI, Lovenberg TW. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J Pharmacol Exp Ther 2009; 330: 142-51.
22. Brisbare-Roch C, Dingemanse J, Koberstein R, Hoever P, Aissaoui H, Flores S, Mueller C, Nayler O, van Gerven J, de Haas SL, Hess P, Qiu C, Buchmann S, Scherz M, Weller T, Fischli W, Clozel M, Jenck F. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med 2007; 13: 150-5.
23. Meerabux J, Iwayama Y, Sakurai T, Ohba H, Toyota T, Yamada K, Nagata R, Irukayama-Tomobe Y, Shimizu H, Yoshitsugu K, Ohta K, Yoshikawa T. Association of an orexin 1 receptor 408Val variant with polydipsia-hyponatremia in schizophrenic subjects. Biol Psychiatry 2005; 58: 401-7.
24. Rainero I, Gallone S, Rubino E, Ponzo P, Valfre W, Binello E, Fenoglio P, Gentile S, Anoaica M, Gasparini M, Pinessi L. Haplotype analysis confi rms the association between the HCRTR2 gene and cluster headache. Headache 2008; 48: 1108-14.
25. Annerbrink K, Westberg L, Olsson M, Andersch S, Sjodin I, Holm G, Allgulander C, Eriksson E. Panic disorder is associated with the Val308Iso polymorphism in the hypocretin receptor gene. Psychiatr Genet 2011; 21: 85-9.
26. Rainero I, Ostacoli L, Rubino E, Gallone S, Picci LR, Fenoglio P, Negro E, Rosso C, De Martino P, De Marchi M, Furlan PM, Pinessi L. Association between major mood disorders and the hypocretin receptor 1 gene. J Affect Disord 2011; 130: 487-91.
27. Hara J, Yanagisawa M, Sakurai T. Difference in obesity phenotype between orexin-knockout mice and orexin neuron-deficient mice with same genetic background and environmental conditions. Neurosci Lett 2005; 380: 239-42.
28. Sellayah D, Bharaj P, Sikder D. Orexin is required for brown adipose tissue development, differentiation, and function. Cell Metab 2011; 14: 478-90.
29. Funato H, Tsai AL, Willie JT, Kisanuki Y, Williams SC, Sakurai T, Yanagisawa M. Enhanced orexin receptor-2 signaling prevents diet-induced obesity and improves leptin sensitivity. Cell Metab 2009; 9: 64-76.
30. Mieda M, Hasegawa E, Kisanuki YY, Sinton CM, Yanagisawa M, Sakurai T. Differential roles of orexin receptor-1 and-2 in the regulation of non-REM and REM sleep. J Neurosci 2011; 31: 6518-26.
31. Sakurai T. Orexins and orexin receptors: Implication in feeding behavior. Regul Pept 1999; 85: 25-30.
32. Li Y, Gao XB, Sakurai T, van den Pol AN. Hypocretin/Orexin excites hypocretin neurons via a local glutamate neuron-A potential mechanism for orchestrating the hypothalamic arousal system. Neuron 2002; 36: 1169-81.
33. Sakurai T, Nagata R, Yamanaka A, Kawamura H, Tsujino N, Muraki Y, Kageyama H, Kunita S, Takahashi S, Goto K, Koyama Y, Shioda S, Yanagisawa M. Input of orexin/hypocretin neurons revealed by a genetically encoded tracer in mice. Neuron 2005; 46: 297-308.
34. Tsunematsu T, Kilduff TS, Boyden ES, Takahashi S, Tominaga M, Yamanaka A. Acute optogenetic silencing of orexin/hypocretin neurons induces slow-wave sleep in mice. J Neurosci 2011; 31: 10529-39.
35. Adamantidis AR, Zhang F, Aravanis AM, Deisseroth K, de Lecea L. Neural substrates of awakening probed with optogenetic control of hypocretin neurons. Nature 2007; 450: 420-4.
36. Hara J, Beuckmann CT, Nambu T, Willie JT, Chemelli RM, Sinton CM, Sugiyama F, Yagami K, Goto K, Yanagisawa M, Sakurai T. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 2001; 30: 345-54.
37. Beuckmann CT, Sinton CM, Williams SC, Richardson JA, Hammer RE, Sakurai T, Yanagisawa M. Expression of a polyglutamine-Ataxin-3 transgene in orexin neurons induces narcolepsy-cataplexy in the rat. J Neurosci 2004; 24: 4469-77.
38. Mieda M, Willie JT, Hara J, Sinton CM, Sakurai T, Yanagisawa M. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-Ablated model of narcolepsy in mice. Proc Natl Acad Sci USA 2004; 101: 4649-54.
39. Miesenbock G. Optogenetic control of cells and circuits. Annu Rev Cell Dev Biol 2011; 27: 731-58.
40. Anaclet C, Parmentier R, Ouk K, Guidon G, Buda C, Sastre JP, Akaoka H, Sergeeva OA, Yanagisawa M, Ohtsu H, Franco P, Haas HL, Lin JS. Orexin/hypocretin and histamine: Distinct roles in the control of wakefulness demonstrated using knock-out mouse models. J Neurosci 2009; 29: 14423-38.
41. Winsky-Sommerer R, Yamanaka A, Diano S, Borok E, Roberts AJ, Sakurai T, Kilduff TS, Horvath TL, de Lecea L. Interaction between the corticotropin-releasing factor system and hypocretins (orexins): A novel circuit mediating stress response. J Neurosci 2004; 24: 11439-48.
42. Louis GW, Leinninger GM, Rhodes CJ, Myers MG Jr. Direct innervation and modulation of orexin neurons by lateral hypothalamic LepRb neurons. J Neurosci 2010; 30: 11278-87.
43. Liu M, Blanco-Centurion C, Konadhode R, Begum S, Pelluru D, Gerashchenko D, Sakurai T, Yanagisawa M, van den Pol AN, Shiromani PJ. Orexin gene transfer into zona incerta neurons suppresses muscle paralysis in narcoleptic mice. J Neurosci 2011; 31: 6028-40.
44. Johnson PL, Truitt W, Fitz SD, Minick PE, Dietrich A, Sanghani S, Traskman-Bendz L, Goddard AW, Brundin L, Shekhar A. A key role for orexin in panic anxiety. Nat Med 2010; 16: 111-5.
45. Nishino S. Hypocretin Measurements in the CSF, and blood and brain tissue. Basic and clinical applications. In: Nishino S, Sakurai T, editors. Chapter 6. Contemporary clinical neuroscience: The orexin/hypocretin system: Physiology and pathophysiology. Totowa, NJ: Humana Press Inc., 2005: 73-82.
46. Sakurai T. The neural circuit of orexin (hypocretin): Maintaining sleep and wakefulness. Nat Rev Neurosci 2007; 8: 171-81.
47. Heinonen MV, Purhonen AK, Makela KA, Herzig KH. Functions of orexins in peripheral tissues. Acta Physiol (Oxf) 2008; 192: 471-85.
48. Scammell TE, Winrow CJ. Orexin receptors: Pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol 2011; 51: 243-66.
49. Perez-Leighton CE, Butterick-Peterson TA, Billington CJ, Kotz CM. Role of orexin receptors in obesity: From cellular to behavioral evidence. Int J Obes (Lond) 2012: In press. doi: 10.1038/ ijo.2012.30.
50. Bayer L, Mairet-Coello G, Risold PY, Griffond B. Orexin/hypocretin neurons: Chemical phenotype and possible interactions with melanin-concentrating hormone neurons. Regul Pept 2002; 104: 33-9.
51. Reti IM, Reddy R, Worley PF, Baraban JM. Selective expression of Narp, a secreted neuronal pentraxin, in orexin neurons. J Neurochem 2002; 82: 1561-5.
52. Maolood N, Meister B. Nociceptin/orphanin FQ peptide in hypothalamic neurones associated with the control of feeding behaviour. J Neuroendocrinol 2010; 22: 75-82.
53. Horvath TL, Diano S, van den Pol AN. Synaptic interaction between hypocretin (orexin) and neuropeptide Y cells in the rodent and primate hypothalamus: A novel circuit implicated in metabolic and endocrine regulations. J Neurosci 1999; 19: 1072-87.
54. Yoshida K, McCormack S, Espana RA, Crocker A, Scammell TE. Afferents to the orexin neurons of the rat brain. J Comp Neurol 2006; 494: 845-61.
55. Sakurai T, Mieda M. Connectomics of orexin-producing neurons: Interface of systems of emotion, energy homeostasis and arousal. Trends Pharmacol Sci 2011; 32: 451-62.
56. Burdakov D, Lesage F. Glucose-induced inhibition: How many ionic mechanisms ? Acta Physiol (Oxf) 2010; 198: 295-301.
57. Karnani MM, Apergis-Schoute J, Adamantidis A, Jensen LT, de Lecea L, Fugger L, Burdakov D. Activation of central orexin/ hypocretin neurons by dietary amino acids. Neuron 2011; 72: 616-29.
58. van den Pol AN. Hypothalamic hypocretin (orexin): Robust innervation of the spinal cord. J Neurosci 1999; 19: 3171-82.
59. Oldfield BJ, Giles ME, Watson A, Anderson C, Colvill LM, McKinley MJ. The neurochemical characterisation of hypothalamic pathways projecting polysynaptically to brown adipose tissue in the rat. Neuroscience 2002; 110: 515-26.
60. Zheng H, Patterson LM, Berthoud HR. Orexin-A projections to the caudal medulla and orexin-induced c-Fos expression, food intake, and autonomic function. J Comp Neurol 2005; 485: 127-42.
61. Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG, Kilduff TS. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998; 18: 9996-10015.
62. Nambu T, Sakurai T, Mizukami K, Hosoya Y, Yanagisawa M, Goto K. Distribution of orexin neurons in the adult rat brain. Brain Res 1999; 827: 243-60.
63. Li Y, van den Pol AN. Differential target-dependent actions of coexpressed inhibitory dynorphin and excitatory hypocretin/ orexin neuropeptides. J Neurosci 2006; 26: 13037-47.
64. Yamanaka A, Tabuchi S, Tsunematsu T, Fukazawa Y, Tominaga M. Orexin directly excites orexin neurons through orexin 2 receptor. J Neurosci 2010; 30: 12642-52.
65. Mochizuki T, Arrigoni E, Marcus JN, Clark EL, Yamamoto M, Honer M, Borroni E, Lowell BB, Elmquist JK, Scammell TE. Orexin receptor 2 expression in the posterior hypothalamus rescues sleepiness in narcoleptic mice. Proc Natl Acad Sci USA 2011; 108: 4471-6.
66. Arrigoni E, Mochizuki T, Scammell TE. Activation of the basal forebrain by the orexin/hypocretin neurones. Acta Physiol (Oxf) 2010; 198: 223-35.
67. Lin JS, Anaclet C, Sergeeva OA, Haas HL. The waking brain: An update. Cell Mol Life Sci 2011; 68: 2499-512.
68. Nishino S. Hypothalamus, hypocretins/orexin, and vigilance control. Handb Clin Neurol 2011; 99: 765-82.
69. Overeem S, Black JL 3rd, Lammers GJ. Narcolepsy: Immunological aspects. Sleep Med Rev 2008; 12: 95-107.
70. Nishino S, Okuro M, Kotorii N, Anegawa E, Ishimaru Y, Matsumura M, Kanbayashi T. Hypocretin/orexin and narcolepsy: New basic and clinical insights. Acta Physiol (Oxf) 2010; 198: 209-22.
71. Fontana A, Gast H, Reith W, Recher M, Birchler T, Bassetti CL. Narcolepsy: Autoimmunity, effector T cell activation due to infection, or T cell independent, major histocompatibility complex class II induced neuronal loss ? Brain 2010; 133: 1300-11.
72. Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, Cornford M, Siegel JM. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000; 27: 469-74.
73. Thannickal TC, Siegel JM, Nienhuis R, Moore RY. Pattern of hypocretin (orexin) soma and axon loss, and gliosis, in human narcolepsy. Brain Pathol 2003; 13: 340-51.
74. Blouin AM, Thannickal TC, Worley PF, Baraban JM, Reti IM, Siegel JM. Narp immunostaining of human hypocretin (orexin) neurons: Loss in narcolepsy. Neurology 2005; 65: 1189-92.
75. Thannickal TC, Nienhuis R, Siegel JM. Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy. Sleep 2009; 32: 993-8.
76. Karteris E, Machado RJ, Chen J, Zervou S, Hillhouse EW, Randeva HS. Food deprivation differentially modulates orexin receptor expression and signalling in the rat hypothalamus and adrenal cortex. Am J Physiol Endocrinol Metab 2005; 288: E1089-100.
77. Flemstrom G, Bengtsson MW, Makela K, Herzig KH. Effects of short-Term food deprivation on orexin-A-induced intestinal bicarbonate secretion in comparison with related secretagogues. Acta Physiol (Oxf) 2010; 198: 373-80.
78. Fujiki N, Yoshida Y, Zhang S, Sakurai T, Yanagisawa M, Nishino S. Sex difference in body weight gain and leptin signaling in hypocretin/orexin deficient mouse models. Peptides 2006; 27: 2326-31.
79. Kok SW, Overeem S, Visscher TL, Lammers GJ, Seidell JC, Pijl H, Meinders AE. Hypocretin deficiency in narcoleptic humans is associated with abdominal obesity. Obes Res 2003; 11: 1147-54.
80. Monda M, Viggiano A, Mondola P, De Luca V. Inhibition of prostaglandin synthesis reduces hyperthermic reactions induced by hypocretin-1/orexin A. Brain Res 2001; 909: 68-74.
81. Wang J, Osaka T, Inoue S. Energy expenditure by intracerebroventricular administration of orexin to anesthetized rats. Neurosci Lett 2001; 315: 49-52.
82. Wang J, Osaka T, Inoue S. Orexin-A-sensitive site for energy expenditure localized in the arcuate nucleus of the hypothalamus. Brain Res 2003; 971: 128-34.
83. Yoshimichi G, Yoshimatsu H, Masaki T, Sakata T. Orexin-A regulates body temperature in coordination with arousal status. Exp Biol Med (Maywood) 2001; 226: 468-76.
84. Haynes AC, Chapman H, Taylor C, Moore GB, Cawthorne MA, Tadayyon M, Clapham JC, Arch JR. Anorectic, thermogenic and anti-obesity activity of a selective orexin-1 receptor antagonist in ob/ob mice. Regul Pept 2002; 104: 153-9.
85. Verty AN, Allen AM, Oldfield BJ. The endogenous actions of hypothalamic peptides on brown adipose tissue thermogenesis in the rat. Endocrinology 2010; 151: 4236-46.
86. Zhang W, Sunanaga J, Takahashi Y, Mori T, Sakurai T, Kanmura Y, Kuwaki T. Orexin neurons are indispensable for stress-induced thermogenesis in mice. J Physiol 2010; 588: 4117-29.
87. Steininger TL, Kilduff TS, Behan M, Benca RM, Landry CF. Comparison of hypocretin/orexin and melanin-concentrating hormone neurons and axonal projections in the embryonic and postnatal rat brain. J Chem Neuroanat 2004; 27: 165-81.
88. Amiot C, Brischoux F, Colard C, La Roche A, Fellmann D, Risold PY. Hypocretin/orexin-containing neurons are produced in one sharp peak in the developing ventral diencephalon. Eur J Neurosci 2005; 22: 531-4.
89. Sakurai T, Moriguchi T, Furuya K, Kajiwara N, Nakamura T, Yanagisawa M, Goto K. Structure and function of human preproorexin gene. J Biol Chem 1999; 274: 17771-6.
90. Nakabayashi M, Suzuki T, Takahashi K, Totsune K, Muramatsu Y, Kaneko C, Date F, Takeyama J, Darnel AD, Moriya T, Sasano H. Orexin-A expression in human peripheral tissues. Mol Cell Endocrinol 2003; 205: 43-50.
91. Virtanen KA, Lidell ME, Orava J, Heglind M, Westergren R, Niemi T, Taittonen M, Laine J, Savisto NJ, Enerback S, Nuutila P. Functional brown adipose tissue in healthy adults. N Engl J Med 2009; 360: 1518-25.
92. van den Top M, Nolan MF, Lee K, Richardson PJ, Buijs RM, Davies CH, Spanswick D. Orexins induce increased excitability and synchronisation of rat sympathetic preganglionic neurones. J Physiol 2003; 549: 809-21.
93. Smith PM, Connolly BC, Ferguson AV. Microinjection of orexin into the rat nucleus tractus solitarius causes increases in blood pressure. Brain Res 2002; 950: 261-7.
94. de Oliveira CV, Rosas-Arellano MP, Solano-Flores LP, Ciriello J. Cardiovascular effects of hypocretin-1 in nucleus of the solitary tract. Am J Physiol Heart Circ Physiol 2003; 284: H1369-77.
95. Yang B, Ferguson AV. Orexin-A depolarizes nucleus tractus solitarius neurons through effects on nonselective cationic and K conductances. J Neurophysiol 2003; 89: 2167-75.
96. Monda M, Viggiano A, Viggiano A, Fuccio F, De Luca V. Injection of orexin A into the diagonal band of Broca induces sympathetic and hyperthermic reactions. Brain Res 2004; 1018: 265-71.
97. Shiuchi T, Haque MS, Okamoto S, Inoue T, Kageyama H, Lee S, Toda C, Suzuki A, Bachman ES, Kim YB, Sakurai T, Yanagisawa M, Shioda S, Imoto K, Minokoshi Y. Hypothalamic orexin stimulates feeding-Associated glucose utilization in skeletal muscle via sympathetic nervous system. Cell Metab 2009; 10: 466-80.
98. Stanley S, Pinto S, Segal J, Perez CA, Viale A, DeFalco J, Cai X, Heisler LK, Friedman JM. Identification of neuronal subpopulations that project from hypothalamus to both liver and adipose tissue polysynaptically. Proc Natl Acad Sci USA 2010; 107: 7024-9.
99. Kuwaki T. Orexin links emotional stress to autonomic functions. Auton Neurosci 2011; 161: 20-7.
100. Spinazzi R, Andreis PG, Rossi GP, Nussdorfer GG. Orexins in the regulation of the hypothalamic-pituitary-Adrenal axis. Pharmacol Rev 2006; 58: 46-57.
101. Harris GC, Wimmer M, Aston-Jones G. A role for lateral hypothalamic orexin neurons in reward seeking. Nature 2005; 437: 556-9.
102. Boutrel B, Kenny PJ, Specio SE, Martin-Fardon R, Markou A, Koob GF, de Lecea L. Role for hypocretin in mediating stressinduced reinstatement of cocaine-seeking behavior. Proc Natl Acad Sci USA 2005; 102: 19168-73.
103. Aston-Jones G, Smith RJ, Sartor GC, Moorman DE, Massi L, Tahsili-Fahadan P, Richardson KA. Lateral hypothalamic orexin/hypocretin neurons: A role in reward-seeking and addiction. Brain Res 2010; 1314: 74-90.
104. Boutrel B, Cannella N, de Lecea L. The role of hypocretin in driving arousal and goal-oriented behaviors. Brain Res 2010; 1314: 103-11.
105. Thompson JL, Borgland SL. A role for hypocretin/orexin in motivation. Behav Brain Res 2011; 217: 446-53.
106. Suzuki M, Beuckmann CT, Shikata K, Ogura H, Sawai T. Orexin-A (hypocretin-1) is possibly involved in generation of anxiety-like behavior. Brain Res 2005; 1044: 116-21.
107. Li Y, Li S, Wei C, Wang H, Sui N, Kirouac GJ. Orexins in the paraventricular nucleus of the thalamus mediate anxietylike responses in rats. Psychopharmacology (Berl) 2010; 212: 251-65.
108. Plaza-Zabala A, Martin-Garcia E, de Lecea L, Maldonado R, Berrendero F. Hypocretins regulate the anxiogenic-like effects of nicotine and induce reinstatement of nicotine-seeking behavior. J Neurosci 2010; 30: 2300-10.
109. Scott MM, Marcus JN, Pettersen A, Birnbaum SG, Mochizuki T, Scammell TE, Nestler EJ, Elmquist JK, Lutter M. Hcrtr1 and 2 signaling differentially regulates depression-like behaviors. Behav Brain Res 2011; 222: 289-94.
110. Bingham S, Davey PT, Babbs AJ, Irving EA, Sammons MJ, Wyles M, Jeffrey P, Cutler L, Riba I, Johns A, Porter RA, Upton N, Hunter AJ, Parsons AA. Orexin-A, an hypothalamic peptide with analgesic properties. Pain 2001; 92: 81-90.
111. Yamamoto T, Nozaki-Taguchi N, Chiba T. Analgesic effect of intrathecally administered orexin-A in the rat formalin test and in the rat hot plate test. Br J Pharmacol 2002; 137: 170-6.
112. Mobarakeh JI, Takahashi K, Sakurada S, Nishino S, Watanabe H, Kato M, Yanai K. Enhanced antinociception by intracerebroventricularly and intrathecally-Administered orexin A and B (hypocretin-1 and-2) in mice. Peptides 2005; 26: 767-77.
113. Watson SL, Watson CJ, Baghdoyan HA, Lydic R. Thermal nociception is decreased by hypocretin-1 and an adenosine A1 receptor agonist microinjected into the pontine reticular formation of Sprague Dawley rat. J Pain 2010; 11: 535-44.
114. Watanabe S, Kuwaki T, Yanagisawa M, Fukuda Y, Shimoyama M. Persistent pain and stress activate pain-inhibitory orexin pathways. Neuroreport 2005; 16: 5-8.
115. Voisin T, Rouet-Benzineb P, Reuter N, Laburthe M. Orexins and their receptors: Structural aspects and role in peripheral tissues. Cell Mol Life Sci 2003; 60: 72-87.
116. Nurmio M, Tena-Sempere M, Toppari J. Orexins and the regulation of the hypothalamic-pituitary-Testicular axis. Acta Physiol (Oxf) 2010; 198: 349-54.
117. Kastin AJ, Akerstrom V. Orexin A but not orexin B rapidly enters brain from blood by simple diffusion. J Pharmacol Exp Ther 1999; 289: 219-23.
118. Schatzberg SJ, Cutter-Schatzberg K, Nydam D, Barrett J, Penn R, Flanders J, deLahunta A, Lin L, Mignot E. The effect of hypocretin replacement therapy in a 3-year-old Weimaraner with narcolepsy. J Vet Int Med 2004; 18: 586-8.
119. Karteris E, Chen J, Randeva HS. Expression of human preproorexin and signaling characteristics of orexin receptors in the male reproductive system. J Clin Endocrinol Metab 2004; 89: 1957-62.
120. Kirchgessner AL, Liu M. Orexin synthesis and response in the gut. Neuron 1999; 24: 941-51.
121. van den Pol AN, Gao XB, Obrietan K, Kilduff TS, Belousov AB. Presynaptic and postsynaptic actions and modulation of neuroendocrine neurons by a new hypothalamic peptide, hypocretin/ orexin. J Neurosci 1998; 18: 7962-71.
122. Date Y, Mondal MS, Matsukura S, Ueta Y, Yamashita H, Kaiya H, Kangawa K, Nakazato M. Distribution of orexin/hypocretin in the rat median eminence and pituitary. Brain Res Mol Brain Res 2000; 76: 1-6.
123. Randeva HS, Karteris E, Grammatopoulos D, Hillhouse EW. Expression of orexin-A and functional orexin type 2 receptors in the human adult adrenals: Implications for adrenal function and energy homeostasis. J Clin Endocrinol Metab 2001; 86: 4808-13.
124. Holmqvist T, Johansson L, ostman M, Ammoun S, A kerman KE, Kukkonen JP. OX1 orexin receptors couple to adenylyl cyclase regulation via multiple mechanisms. J Biol Chem 2005; 280: 6570-9.
125. Duguay D, Belanger-Nelson E, Mongrain V, Beben A, Khatchadourian A, Cermakian N. Dynein light chain Tctex-Type 1 modulates orexin signaling through its interaction with orexin 1 receptor. PLoS One 2011; 6: E26430.
126. El Firar A, Voisin T, Rouyer-Fessard C, Ostuni MA, Couvineau A, Laburthe M. Discovery of a functional immunoreceptor tyrosine-based switch motif in a 7-Transmembrane-spanning receptor: Role in the orexin receptor OX1R-driven apoptosis. FASEB J 2009; 23: 4069-80.
127. Milasta S, Evans NA, Ormiston L, Wilson S, Lefkowitz RJ, Milligan G. The sustainability of interactions between the orexin-1 receptor and ?-Arrestin-2 is defined by a single C-Terminal cluster of hydroxy amino acids and modulates the kinetics of ERK MAPK regulation. Biochem J 2005; 387: 573-84.
128. Kukkonen JP, A kerman KEO. Intracellular signal pathways utilized by the hypocretin/orexin receptors. In: De Lecea L, Sutcliffe JG, editors. Hypocretins as integrators of physiological signals. Berlin, Germany: Springer Science+ Business Media, 2005: 221-31.
129. Lund PE, Shariatmadari R, Uustare A, Detheux M, Parmentier M, Kukkonen JP, A kerman KEO. The orexin OX1 receptor activates a novel Ca 2+ influx pathway necessary for coupling to phospholipase C. J Biol Chem 2000; 275: 30806-12.
130. Ekholm ME, Johansson L, Kukkonen JP. IP(3)-independent signalling of OX(1) orexin/hypocretin receptors to Ca(2+ ) influx and ERK. Biochem Biophys Res Commun 2007; 353: 475-80.
131. Zhang L, Kolaj M, Renaud LP. Ca 2+-dependent and Na+-dependent K+conductances contribute to a slow AHP in thalamic paraventricular nucleus neurons: A novel target for orexin receptors. J Neurophysiol 2010; 104: 2052-62.
132. Horvath TL, Peyron C, Diano S, Ivanov A, Aston-Jones G, Kilduff TS, van Den Pol AN. Hypocretin (orexin) activation and synaptic innervation of the locus coeruleus noradrenergic system. J Comp Neurol 1999; 415: 145-59.
133. Hoang QV, Bajic D, Yanagisawa M, Nakajima S, Nakajima Y. Effects of orexin (hypocretin) on GIRK channels. J Neurophysiol 2003; 90: 693-702.
134. Kukkonen JP. A m é nage à trois made in heaven: G-proteincoupled receptors, lipids and TRP channels. Cell Calcium 2011; 50: 9-26.
135. Näsman J, Bart G, Larsson K, Louhivuori L, Peltonen H, A kerman KE. The orexin OX1 receptor regulates Ca 2+ entry via diacylglycerol-Activated channels in differentiated neuroblastoma cells. J Neurosci 2006; 26: 10658-66.
136. Acuna-Goycolea C, van den Pol AN. Neuroendocrine proopiomelanocortin neurons are excited by hypocretin/orexin. J Neurosci 2009; 29: 1503-13.
137. Louhivuori LM, Jansson L, Nordstrom T, Bart G, Nasman J, Akerman KE. Selective interference with TRPC3/6 channels disrupts OX1 receptor signalling via NCX and reveals a distinct calcium influx pathway. Cell Calcium 2010; 48: 114-23.
138. Johansson L, Ekholm ME, Kukkonen JP. Multiple phospholipase activation by OX(1) orexin/hypocretin receptors. Cell Mol Life Sci 2008; 65: 1948-56.
139. Turunen PM, Ekholm ME, Somerharju P, Kukkonen JP. Arachidonic acid release mediated by OX(1) orexin receptors. Br J Pharmacol 2010; 159: 212-21.
140. Jäntti MH, Putula J, Somerharju P, Frohman MA, Kukkonen JP. OX(1) orexin/hypocretin receptor activation of phospholipase D. Br J Pharmacol 2012; 165: 1109-23.
141. Turunen PM, Jäntti MH, Kukkonen JP. OX1 orexin/hypocretin receptor signaling via arachidonic acid and endocannabinoid release. Mol Pharmacol 2012; in press. doi: 10.1124/ mol.112.078063.
142. Ammoun S, Johansson L, Ekholm ME, Holmqvist T, Danis AS, Korhonen L, Sergeeva OA, Haas HL, A kerman KE, Kukkonen JP. OX1 orexin receptors activate extracellular signal-regulated kinase (ERK) in CHO cells via multiple mechanisms: The role of Ca 2+ influx in OX1 receptor signaling. Mol Endocrinol 2006; 20: 80-99.
143. Borgland SL, Taha SA, Sarti F, Fields HL, Bonci A. Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine. Neuron 2006; 49: 589-601.
144. Shin HS, Cho HS, Sung KW, Yoon BJ. Orexin-A increases cell surface expression of AMPA receptors in the striatum. Biochem Biophys Res Commun 2009; 378: 409-13.
145. Selbach O, Bohla C, Barbara A, Doreulee N, Eriksson KS, Sergeeva OA, Haas HL. Orexins/hypocretins control bistability of hippocampal long-Term synaptic plasticity through coactivation of multiple kinases. Acta Physiol (Oxf) 2010; 198: 277-85.
146. Rouet-Benzineb P, Rouyer-Fessard C, Jarry A, Avondo V, Pouzet C, Yanagisawa M, Laboisse C, Laburthe M, Voisin T. Orexins acting at native OX(1) receptor in colon cancer and neuroblastoma cells or at recombinant OX(1) receptor suppress cell growth by inducing apoptosis. J Biol Chem 2004; 279: 45875-86.
147. Ammoun S, Lindholm D, Wootz H, A kerman KE, Kukkonen JP. G-protein-coupled OX1 orexin/hcrtr-1 hypocretin receptors induce caspase-dependent and-independent cell death through p38 mitogen-/stress-Activated protein kinase. J Biol Chem 2006; 281: 834-42.
148. Voisin T, El Firar A, Fasseu M, Rouyer-Fessard C, Descatoire V, Walker F, Paradis V, Bedossa P, Henin D, Lehy T, Laburthe M. Aberrant expression of OX1 receptors for orexins in colon cancers and liver metastases: An openable gate to apoptosis. Cancer Res 2011; 71: 3341-51.
149. Porter RA, Chan WN, Coulton S, Johns A, Hadley MS, Widdowson K, Jerman JC, Brough SJ, Coldwell M, Smart D, Jewitt F, Jeffrey P, Austin N. 1, 3-Biarylureas as selective nonpeptide antagonists of the orexin-1 receptor. Bioorg Med Chem Lett 2001; 11: 1907-10.
150. Chen J, Karteris E, Collins D, Randeva HS. Differential expression of mouse orexin receptor type-2 (OX2R) variants in the mouse brain. Brain Res 2006; 1103: 20-4.